ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 752

Potential Roles of Toll-like Receptor 4 in the Murine Models of Systemic Sclerosis

Takehiro Takahashi, Yoshihide Asano, Yohei Ichimura, Tetsuo Toyama, Takashi Taniguchi, Shinji Noda, Kaname Akamata and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: fibrosis, innate immunity, systemic sclerosis and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Bleomycin (BLM)-induced fibrosis model and tight skin mice (TSK/+) model are well-established experimental murine models of human systemic sclerosis (SSc). Growing evidence has demonstrated the pivotal role of Toll-like receptors (TLRs) in several autoimmune inflammatory diseases including SSc. The aim of this study is to determine the role of TLR4 in the fibrotic process in these models.

Methods: We generated a BLM-induced SSc murine model with mice deficient for TLR4. The mechanism by which TLR4 contributes to this fibrotic model was investigated with histologic examination, hydroxyproline assay, ELISA, real-time PCR, and flow cytometry. In addition, to examine the role of TLR4 in less inflammatory fibrotic model, we also investigated fibrosis in TSK/+ mice lacking TLR4.

Results: Dermal and lung fibrosis was attenuated in BLM-treated TLR4-/- mice compared with their wild type counterparts. Consistently, inflammatory cell infiltration, expression of various inflammatory cytokines, pathological angiogenesis, hypergammaglobulinemia and elevated titer of anti-DNA topoisomerase I antibody induced by BLM treatment were suppressed with TLR4 deletion. Furthermore, the increased expression of interleukin (IL)-6 in fibroblasts, endothelial cells, and immune cells in response to BLM in vivo and to LPS in vitrowas remarkably abrogated in the absence of TLR4. Moreover, TLR4 deletion was associated with alleviated skew in Th2/Th17 response against BLM treatment. In parallel with these observations, TLR4 abrogation attenuated skin fibrosis in TSK/+ mice as well.

Conclusion: These results indicate the pivotal contribution of TLR4 to the pathogenesis in a BLM-induced SSc murine model and TSK/+ model, two major models which mimic early and late phase of SSc respectively. Our results indicate the critical role of TLR4 signaling in the pathogenesis of fibrosis, suggesting that the biomolecular TLR4 targeting might be a potential therapeutic approach to SSc.


Disclosure:

T. Takahashi,
None;

Y. Asano,
None;

Y. Ichimura,
None;

T. Toyama,
None;

T. Taniguchi,
None;

S. Noda,
None;

K. Akamata,
None;

S. Sato,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/potential-roles-of-toll-like-receptor-4-in-the-murine-models-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology